Published in J Biol Chem on March 10, 2000
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
Cancer-related inflammation. J Clin Immunol (2012) 1.91
Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell (2007) 1.61
Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer (2004) 1.56
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res (2008) 1.53
The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res (2011) 1.44
Breakdown of the endothelial barrier function in tumor cell transmigration. Biophys J (2007) 1.39
Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-calpain. Mol Cell Biol (2005) 1.35
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer (2009) 1.27
Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest (2006) 1.26
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol (2008) 1.24
The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncol (2013) 1.22
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res (2009) 1.17
Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res (2013) 1.16
Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis (2008) 1.14
CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol (2007) 1.08
Immune and Inflammatory Responses in GERD and Lansoprazole. J Clin Biochem Nutr (2007) 1.01
Interleukin-8 in breast cancer progression. J Interferon Cytokine Res (2013) 1.00
Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells. Int J Biol Sci (2011) 0.99
Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinog (2011) 0.99
Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol (2009) 0.96
Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int J Cancer (2010) 0.94
Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem (2010) 0.94
CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res (2011) 0.94
Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol (2010) 0.93
Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol Cancer Ther (2013) 0.93
Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol (2009) 0.92
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem (2009) 0.90
Calcium mobilization triggered by the chemokine CXCL12 regulates migration in wounded intestinal epithelial monolayers. J Biol Chem (2010) 0.90
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res (2008) 0.87
CXCR2: a target for pancreatic cancer treatment? Expert Opin Ther Targets (2013) 0.87
Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment. Exp Cell Res (2014) 0.86
Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. J Biol Chem (2017) 0.84
Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod Biol Endocrinol (2003) 0.84
Chemokines, chemokine receptors and the gastrointestinal system. World J Gastroenterol (2013) 0.82
Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma. Exp Ther Med (2012) 0.82
Expression of C-X-C chemokine receptor types 1/2 in patients with gastric carcinoma: Clinicopathological correlations and significance. Oncol Lett (2012) 0.79
Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil. Int J Oncol (2016) 0.78
CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells. PLoS One (2012) 0.78
Seminal plasma enhances cervical adenocarcinoma cell proliferation and tumour growth in vivo. PLoS One (2012) 0.78
EGFR signaling in renal fibrosis. Kidney Int Suppl (2011) (2014) 0.77
FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene (2017) 0.77
Water-soluble egg membrane enhances the immunoactivating properties of an Aloe vera-based extract of Nerium oleander leaves. Clin Cosmet Investig Dermatol (2016) 0.75
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science (1985) 7.70
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther (2009) 4.98
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Human T lymphotropic virus type III infection of human alveolar macrophages. Blood (1986) 3.66
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
The acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.49
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med (1989) 2.95
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood (1999) 2.43
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med (1987) 2.31
Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med (1985) 2.20
Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem (1995) 2.17
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 1.98
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol (1993) 1.98
Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature (1987) 1.91
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med (1990) 1.89
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann Intern Med (1986) 1.88
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol (1987) 1.83
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 1.78
Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses (1987) 1.65
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest (1989) 1.61
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer (2007) 1.53
The histiocytic disorders: a pathophysiologic analysis. Ann Intern Med (1981) 1.50
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 1.47
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Immune (gamma) interferon produced by a human T-lymphoblast cell line. Nature (1981) 1.45
Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. J Infect Dis (1992) 1.44
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem (1999) 1.44
Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol (1991) 1.41
HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood (2001) 1.40
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene (1996) 1.40
Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J Virol (1989) 1.38
Behavioral risk factors for HIV infection among homosexual men at a Boston community health center. Am J Public Health (1988) 1.37
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene (2009) 1.35
Hematologic manifestations of the human immune deficiency virus (HIV). Semin Hematol (1988) 1.34
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem (1994) 1.33
Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev (2001) 1.32
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev (1997) 1.31
HTLV-III infection among health care workers. Association with needle-stick injuries. JAMA (1985) 1.31
The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood (1998) 1.30
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol (1998) 1.28
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells. J Virol (1990) 1.28
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem (1997) 1.27
Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood (1994) 1.26
Epidemic of the acquired immunodeficiency syndrome: a need for economic and social planning. Ann Intern Med (1983) 1.24
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem (1997) 1.23
Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection. J Clin Microbiol (1986) 1.22
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol (1995) 1.21
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia (2010) 1.20
Pathophysiology and management of HIV-associated hematologic disorders. Blood (1989) 1.20
CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells. J Virol (1990) 1.20
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood (2000) 1.19
Stromal cell-derived factor-1 alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. J Immunol (1998) 1.18
Pathogenesis of B cell lymphoma in a patient with AIDS. Blood (1986) 1.18
Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol (1987) 1.18
Antibodies to human T-lymphotropic virus type III (HTLV-III) in saliva of acquired immunodeficiency syndrome (AIDS) patients and in persons at risk for AIDS. Blood (1986) 1.17
Immunogenic nature of a Pol gene product of HTLV-III/LAV. Blood (1987) 1.17
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med (2003) 1.15
HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood (2000) 1.12
Effects of the stem cell factor, c-kit ligand, on human megakaryocytic cells. Blood (1992) 1.11
Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiency virus type 1 (HIV-1). J Infect Dis (1990) 1.11
Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol (2010) 1.10
Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog (2000) 1.09
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem (1997) 1.07
Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. Blood (1985) 1.07
Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem (1994) 1.06
Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood (1990) 1.05
Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.04
RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes. J Exp Med (1997) 1.04
Bacterial expression of the acquired immunodeficiency syndrome retrovirus p24 gag protein and its use as a diagnostic reagent. Proc Natl Acad Sci U S A (1985) 1.04
Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J Biol Chem (2001) 1.03
Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia (1998) 1.03
Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene (2007) 1.03
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem (2000) 1.03